The recent deciphering of activating or inactivating mutations affecting the RHOA GTPase and/or its complexes networks in hematological cancers strongly support the notion that, similarly to solid tumors, RHOA can exert pro- or anti-tumorigenic functions depending on the cell context and tumor type. Here, RHOA is linked to hematopoietic and lymphoid cell neoplasm.